DOCSLIB.ORG

Acid Secretagogue Action of Structurally Gamma-Aminobutyric Acid (GABA)-Related Compounds in Rats

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Acid Secretagogue Action of Structurally Gamma-Aminobutyric Acid (GABA)-Related Compounds in Rats Acid Secretagogue Action of Structurally Gamma-Aminobutyric Acid (GABA)-Related Compounds in Rats Katsuya YAMASAKI and Yoshiaki GOTO* Department of Pharmacology, Tokushima Bunri University, Yamashiro-cho, Tokushima 770, Japan Accepted October 13, 1989 Abstract-The properties of GABA related compounds on gastric function were studied in standardized perfused rat stomach preparations. Intravenous GABA (400 mg/kg) produced a rapid increase in acid secretion. Acid secretagogue actions of 3-aminobutyric acid and 2-aminobutyric acid were less potent than that of GABA. Intravenous injection of 5-amino-n-valeric acid (400 mg/kg) stimulated gastric acid secretion, but 6-amino-n-caproic acid was inactive. Isoguvacine (40 mg/kg, s.c.) stimulated acid output, whereas guvacine, an isomer of isoguvacine, did not. Systemically administered 3-hydroxy-GABA and 8-(p-chlorophenyl) GABA (PCPGABA) showed significant secretagogue actions. Acid responses to GABA-related compounds were significantly reduced by surgical truncal vagotomy and completely antagonized by atropine. The acid responses to PCPGABA and isoguvacine were partially augmented by yohimbine and propranolol. These results suggest that the secretagogue action of GABA is mimicked by structurally GABA-related compounds, which is mediated through cholinergic receptors, with slight implication of alpha-2 and beta-adrenoceptor mechanisms. It is well-established that the central (13, 14). GABAergic mechanisms to stimu nervous system participates in the regulation late acid secretion are, however, complicated of gastric acid secretion (1). The relationships because both types of GABAA and GABAB between neurotransmitters and gastric acid receptor agonists stimulate gastric acid secre secretion were widely studied with regard to tion responses. There is no evidence to show aspects such as inhibitory effects of norepi that GABA mechanisms in the regulation of nephrine (2), dopamine (3), calcitonin-gene gastric secretion is selectively activated by related peptide (CGRP) (4), nicotine (5), GABA or a GABA-moiety. This led us to ex bombesin (6), neurotensin (7) and somato plore the effect of structurally GABA-related statin (8) and secretagogue effects of nicotine compounds on gastric secretion. (9) and thyrotropin-releasing hormone (TRH) In the present study, we examined the ef (10). Gamma -amino-n-butyric acid (GABA) fect of various types of GABA-related com is well-established as an inhibitory transmitter pounds on gastric acid secretion by the route in the CNS. We previously reported that of intravenous administration in most cases GABA produced a dose-dependent increase because of its quick or rapid onset to cause in gastric acid secretion (11 ); and also a certain changes. We also compared the effect lipophilic derivative of GABA, 3-(p-chloro of GABA with those of other amino acids that phenyl)-GABA (PCPGABA), stimulated gas have chemical structures similar to GABA, tric acid secretion more potently at a small with special reference to structure-activity dose (2-8 mg/kg, s.c.) (12). The acid secre relationships, and also attempted to define the tagogue effects of GABA and GAB,^-A-mimetics autonomic neuronal mechanisms involved. have been also confirmed in dogs and humans Materials and Methods * To whoa, correspondence should be addressed . Measurement for gastric acid secretion: Male Wistar rats weighing 180-240 g were The cervical ligation of the esophagus was fasted in meta! cages with mesh bottoms for followed by resections of the cervical truncal 18-24 hr prior to the experiment but were vagi. Vagotomy was performed 30 min prior allowed free access to water ad libitum. Rats toa dministration of GABA or GABA-related were anesthetized with urethane (1.25 g/kg, compounds. i.p.). A cannula was inserted into the trachea Drugs: The drugs used were as follows: 4 followed by the ligation of the esophagus to amino-n-butyric acid (GABA), DL-2-amino avoid the reflex of the perfusate. A laparotomy n-butyric acid (2A-BA), DL-3-amino-n was performed, and the pylorus was ligated, butyric acid (3A-BA), 5-amino-n-valeric acid care being taken not to interfere with the (5A-VA), 6-amino-n-caproic acid (6A-CA), vascular supply and neural connections to the DL-4-amino -3-hydroxy-n-butyric acid stomach. A small incision on the forestomach (GABOB), atropine sulfate, yohimbine hy was made, and the gastrib lumen was gently drochloride, and DL-propranolol hydro rinsed with saline to remove the solid gastric chloride, which were all purchased from contents. A dual polyethylene cannula was Nacalai Tesque Ltd., Japan. Isoguvacine and introduced into the gastric lumen through the guvacine were from Funacoshi Pharm. Co., forestomach. The stomach was perfused with Japan; and DL-4-amino-3-(p-chloro saline, pH adjusted to 5.5 by HCI, using a phenyl)-butyric acid (PCPGABA) was a peristaltic pump at a flow rate of 5 ml/min. generous gift from Ciba-Geigy, U.S.A. The Acid output was determined by titrating the chemical structures of these GABA-related perfusate with 0.02 N NaOH to pH 5.5 using compounds are shown in Fig. 1. The com an automatic titrator (Toa Electronic Co. Ltd, pounds dissolved in saline or distilled water Japan. TSB-10A) and continuously recorded were administered through the femoral vein or in terms of every 2 min response via a zero administered subcutaneously. Pretreatment suppression adaptor (Toa Electronic Co. Ltd, with atropine, yohimbine or propranolol was Japan, C96667T). Acid output was expressed performed 20 min before each secretagogue in terms of /i equivalents of hydrogen ions was administered. (freq.). After stabilization of basal acid secre Statistical analysis: Results are expressed tion for usually 30 min after the initiation of as the mean±S.E. Basal acid output was very the gastric lumen perfusion, each compound low and usually less than 2.0 aeq./10 min. was intravenously or subcutaneously given at For evaluation of drug effects, the net in a volume of 1 or 2 ml/kg. crease in gastric acid output was calculated Fig. 1. Chemical structures of GABA-related compounds used in this study. by subtracting the basal response from the little or no secretagogue actions. Intravenous acid response to each compound. Statistical injection of 5A-VA (400 mg/kg) and GABOB significances were determined by analysis of (200 mg/kg) markedly stimulated gastric variance followed by Dunnett's test for multi secretion, reaching maximal responses of group comparison of parametric data. 12.1±2.0 ueq./10 min (70 min after, N=6) and 7.2±1.5 ueq./10 min (60 min after, N=6), Results respectively. Isoguvacine also showed a Effect of GABA-related compounds on potent secretagogue effect at the dose of 40 gastric acid secretion: Typical responses of mg/kg, s.c. (maximal response: 15.7±3.2 GABA-related compounds on basal acid ueq./10 min at 90 min after the medication, secretion are shown in Fig. 2. GABA (400 N=6), while guvacine had no influence on mg/kg) given intravenously significantly in gastric acid secretion. Dose-response rela creased the gastric acid production. The tions of 5A-VA, GABOB and isoguvacine secretagogure effect was observed with 15 were also confirmed at the dose ranges of min latency and maintained for more than 120 100-400 mg/kg, i.v.; 50-200 mg/kg, i.v.; and min. The maximal response to GABA was 10-40 mg/kg, s.c., respectively. PC PGABA observed 60 min after the administration and was more than 100-fold potent than GABA was 8.4+1.2 ueq./10 min (N=7). The acid on a molecular basis. PCPGABA (4 mg/kg, secretagogue action of GABA was dose s.c.) exhibited secretagogue action and its dependent (100-400 mg/kg, i.v.). The effect peak response was obtained within 90 min of GABA in anesthetized rats was mimicked (25.6±4.3 ueq./10 min (N=10)). Beth by 5A-VA, GABOB, isoguvacine and PCP anechol (1 mg/kg) and histamine (10 mg/kg) GABA. The results obtained with structurally given subcutaneously caused potent acid related compounds are summarized in Fig. 3. increments, and the peak responses were 3A-BA, 2A-BA and 6A-CA, however, had 16.6±1.8 (30 min, N=10) and 17.7±2.9 (70 Fig. 2. Typical secretory responses to GABA, 5-aminovalleric acid (5A-VA), 4-amino-3-hydroxybutyric acid (GABOB) and isoguvacine in stornach perfused rats. Fig. 3. Secretagogue action of GABA-related compounds in rats . Each column represents the ne increase in gastric acid output for 60 min. GABA (400 mg/kg, i.v.), 3A-BA (400 mg/kg , i.v.), 2A-BA (400 mg/kg, i.v.), 5A-VA (400 mg/kg, i.v.), 6A-CA (400 mg/kg, i.v.), GABOB (200 mg/kg, i.v.), iso guvacine (40 mg/kg, s.c.), guvacine (40 mg/kg, s.c.), PCPGABA (4 mg/kg, s.c.), bethanechol (1 mg, kg, s.c.) and histamine (10 mg/kg , s.c.). Table 1. Influence of atropine and vagotomy on gastric acid response to GABA-related compounds in rats Atropine was subcutaneously pretreated 20 min before administration of GABA-related compounds . Each value represents the mean+S .E. of the net increase of acid output (,Ueq./60 min). 5A-VA: 5 aminovaleric acid, PCPGABA: fi-(p-chlorophenyl)-GABA . A significant difference was obtained from the secretagogue alone at the level of *: P 0.05 by Dunnett's test. The number of rats is indicated in parentheses. min, N=10) /eeq./10 min, respectively. compared to vagi-intact rats. When GABA Influence of cholinergic blockades on (400 mg/kg, i.v.), 5A-VA (400 mg/kg, i.v.), gastric acid response to GABA-related com isoguvacine (40 mg/kg, s.c.) and PCPGABA pounds: The results of the effectiveness of (4 mg/kg, s.c.) were given to vagotomized surgical and chemical vagotomy on the acid rats, the secretagogue actions of these com secretion in response to GABA-related com pounds were significantly attenuated, while pounds are shown in Table 1.
Load more

Recommended publications
  • Neurotransmitters-Drugs Andbrain Function.Pdf
    Neurotransmitters, Drugs and Brain Function. Edited by Roy Webster Copyright & 2001 John Wiley & Sons Ltd ISBN: Hardback 0-471-97819-1 Paperback 0-471-98586-4 Electronic 0-470-84657-7 Neurotransmitters, Drugs and Brain Function Neurotransmitters, Drugs and Brain Function. Edited by Roy Webster Copyright & 2001 John Wiley & Sons Ltd ISBN: Hardback 0-471-97819-1 Paperback 0-471-98586-4 Electronic 0-470-84657-7 Neurotransmitters, Drugs and Brain Function Edited by R. A. Webster Department of Pharmacology, University College London, UK JOHN WILEY & SONS, LTD Chichester Á New York Á Weinheim Á Brisbane Á Singapore Á Toronto Neurotransmitters, Drugs and Brain Function. Edited by Roy Webster Copyright & 2001 John Wiley & Sons Ltd ISBN: Hardback 0-471-97819-1 Paperback 0-471-98586-4 Electronic 0-470-84657-7 Copyright # 2001 by John Wiley & Sons Ltd. Bans Lane, Chichester, West Sussex PO19 1UD, UK National 01243 779777 International ++44) 1243 779777 e-mail +for orders and customer service enquiries): [email protected] Visit our Home Page on: http://www.wiley.co.uk or http://www.wiley.com All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, scanning or otherwise, except under the terms of the Copyright, Designs and Patents Act 1988 or under the terms of a licence issued by the Copyright Licensing Agency Ltd, 90 Tottenham Court Road, London W1P0LP,UK, without the permission in writing of the publisher. Other Wiley Editorial Oces John Wiley & Sons, Inc., 605 Third Avenue, New York, NY 10158-0012, USA WILEY-VCH Verlag GmbH, Pappelallee 3, D-69469 Weinheim, Germany John Wiley & Sons Australia, Ltd.
    [Show full text]
  • GABA Receptors
    D Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews Review No.7 / 1-2011 GABA receptors Wolfgang Froestl , CNS & Chemistry Expert, AC Immune SA, PSE Building B - EPFL, CH-1015 Lausanne, Phone: +41 21 693 91 43, FAX: +41 21 693 91 20, E-mail: [email protected] GABA Activation of the GABA A receptor leads to an influx of chloride GABA ( -aminobutyric acid; Figure 1) is the most important and ions and to a hyperpolarization of the membrane. 16 subunits with γ most abundant inhibitory neurotransmitter in the mammalian molecular weights between 50 and 65 kD have been identified brain 1,2 , where it was first discovered in 1950 3-5 . It is a small achiral so far, 6 subunits, 3 subunits, 3 subunits, and the , , α β γ δ ε θ molecule with molecular weight of 103 g/mol and high water solu - and subunits 8,9 . π bility. At 25°C one gram of water can dissolve 1.3 grams of GABA. 2 Such a hydrophilic molecule (log P = -2.13, PSA = 63.3 Å ) cannot In the meantime all GABA A receptor binding sites have been eluci - cross the blood brain barrier. It is produced in the brain by decarb- dated in great detail. The GABA site is located at the interface oxylation of L-glutamic acid by the enzyme glutamic acid decarb- between and subunits. Benzodiazepines interact with subunit α β oxylase (GAD, EC 4.1.1.15). It is a neutral amino acid with pK = combinations ( ) ( ) , which is the most abundant combi - 1 α1 2 β2 2 γ2 4.23 and pK = 10.43.
    [Show full text]
  • Cell Surface Mobility of GABAB Receptors Saad Bin
    Cell surface mobility of GABAB receptors Saad Bin Hannan September 2011 A thesis submitted in fulfilment of the requirements for the degree of Doctor of Philosophy of the University College London Department of Neuroscience, Physiology, and Pharmacology University College London Gower Street London WC1E 6BT UK Declaration ii ‘I, Saad Hannan confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis.' ____________________ Saad Hannan September 2011 To Ammu, Abbu, Polu Abstract ivi Abstract Type-B γ-aminobutyric acid receptors (GABABRs) are important for mediating slow inhibition in the central nervous system and the kinetics of their internalisation and lateral mobility will be a major determinant of their signalling efficacy. Functional GABABRs require R1 and R2 subunit co-assembly, but how heterodimerisation affects the trafficking kinetics of GABABRs is unknown. Here, an α- bungarotoxin binding site (BBS) was inserted into the N-terminus of R2 to monitor receptor mobility in live cells. GABABRs are internalised via clathrin- and dynamin- dependent pathways and recruited to endosomes. By mutating the BBS, a new technique was developed to differentially track R1a and R2 simultaneously, revealing the subunits internalise as heteromers and that R2 dominantly-affects constitutive internalisation of GABABRs. Notably, the internalisation profile of R1aR2 heteromers, but not R1a homomers devoid of their ER retention motif (R1ASA), is similar to R2 homomers in heterologous systems. The internalisation of R1aASA was slowed to that of R2 by mutating a di-leucine motif in the R1 C-terminus, indicating a new role for heterodimerisation, whereby R2 subunits slow the internalization of surface GABABRs.
    [Show full text]
  • Isoguvacine Hydrochloride | Medchemexpress
    Inhibitors Product Data Sheet Isoguvacine hydrochloride • Agonists Cat. No.: HY-100810 CAS No.: 68547-97-7 Molecular Formula: C₆H₁₀ClNO₂ • Molecular Weight: 163.6 Screening Libraries Target: GABA Receptor Pathway: Membrane Transporter/Ion Channel; Neuronal Signaling Storage: Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month SOLVENT & SOLUBILITY In Vitro H2O : ≥ 100 mg/mL (611.25 mM) DMSO : 25 mg/mL (152.81 mM; Need ultrasonic) * "≥" means soluble, but saturation unknown. Mass Solvent 1 mg 5 mg 10 mg Concentration Preparing 1 mM 6.1125 mL 30.5623 mL 61.1247 mL Stock Solutions 5 mM 1.2225 mL 6.1125 mL 12.2249 mL 10 mM 0.6112 mL 3.0562 mL 6.1125 mL Please refer to the solubility information to select the appropriate solvent. In Vivo 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (12.71 mM); Clear solution 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (12.71 mM); Clear solution 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (12.71 mM); Clear solution BIOLOGICAL ACTIVITY Description Isoguvacine hydrochloride is a GABA receptor agonist. IC₅₀ & Target GABA[1] In Vitro Isoguvacine binds to a mouse forebrain synaptic membrane preparation. The specific binding is displaceable by GABA, Page 1 of 2 www.MedChemExpress.com muscimol and bicuculline but not by picrotoxin or diaminobutyric acid.
    [Show full text]
  • Gabaergic Signaling Linked to Autophagy Enhances Host Protection Against Intracellular Bacterial Infections
    ARTICLE DOI: 10.1038/s41467-018-06487-5 OPEN GABAergic signaling linked to autophagy enhances host protection against intracellular bacterial infections Jin Kyung Kim1,2,3, Yi Sak Kim1,2,3, Hye-Mi Lee1,3, Hyo Sun Jin4, Chiranjivi Neupane 2,5, Sup Kim1,2,3, Sang-Hee Lee6, Jung-Joon Min7, Miwa Sasai8, Jae-Ho Jeong 9,10, Seong-Kyu Choe11, Jin-Man Kim12, Masahiro Yamamoto8, Hyon E. Choy 9,10, Jin Bong Park 2,5 & Eun-Kyeong Jo1,2,3 1234567890():,; Gamma-aminobutyric acid (GABA) is the principal inhibitory neurotransmitter in the brain; however, the roles of GABA in antimicrobial host defenses are largely unknown. Here we demonstrate that GABAergic activation enhances antimicrobial responses against intracel- lular bacterial infection. Intracellular bacterial infection decreases GABA levels in vitro in macrophages and in vivo in sera. Treatment of macrophages with GABA or GABAergic drugs promotes autophagy activation, enhances phagosomal maturation and antimicrobial responses against mycobacterial infection. In macrophages, the GABAergic defense is mediated via macrophage type A GABA receptor (GABAAR), intracellular calcium release, and the GABA type A receptor-associated protein-like 1 (GABARAPL1; an Atg8 homolog). Finally, GABAergic inhibition increases bacterial loads in mice and zebrafish in vivo, sug- gesting that the GABAergic defense plays an essential function in metazoan host defenses. Our study identified a previously unappreciated role for GABAergic signaling in linking antibacterial autophagy to enhance host innate defense against intracellular bacterial infection. 1 Department of Microbiology, Chungnam National University School of Medicine, Daejeon 35015, Korea. 2 Department of Medical Science, Chungnam National University School of Medicine, Daejeon 35015, Korea.
    [Show full text]
  • Certificate of Analysis
    Print Date: Jan 8th 2016 Certificate of Analysis www.tocris.com Product Name: Guvacine hydrochloride Catalog No.: 0234 Batch No.: 13 CAS Number: 6027-91-4 IUPAC Name: 1,2,5,6-Tetrahydropyridine-3-carboxylic acid hydrochloride 1. PHYSICAL AND CHEMICAL PROPERTIES Batch Molecular Formula: C6H9NO2.HCl Batch Molecular Weight: 163.6 Physical Appearance: White crystalline solid Solubility: water to 100 mM phosphate buffered saline to 100 mM Storage: Store at RT Batch Molecular Structure: 2. ANALYTICAL DATA TLC: Rf = 0.35 (Pyridine:Acetic acid:Water:Butanol [3:8:11:33]) Melting Point: Greater than 250°C 1H NMR: Consistent with structure Microanalysis: Carbon Hydrogen Nitrogen Theoretical 44.05 6.16 8.56 0 0 0 Found 43.52 6.28 8.42 0 0 0 Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use bio-techne.com North America China Europe Middle East Africa Rest of World [email protected] Tel: (800) 343 7475 [email protected] Tel: +44 (0)1235 529449 www.tocris.com/distributors [email protected] Tel: +86 (21) 52380373 Tel:+1 612 379 2956 Print Date: Jan 8th 2016 Product Information www.tocris.com Product Name: Guvacine hydrochloride Catalog No.: 0234 Batch No.: 13 CAS Number: 6027-91-4 IUPAC Name: 1,2,5,6-Tetrahydropyridine-3-carboxylic acid hydrochloride Description: Storage: Store at RT Specific GABA uptake inhibitor. IC values are 14, 58, 119 and 50 Solubility & Usage Info: 1870 μM for hGAT-1, rGAT-2, hGAT-3 and hBGT-1 respectively. water to 100 mM Physical and Chemical Properties: phosphate buffered saline to 100 mM Batch Molecular Formula: C H NO .HCl 69 2 Stability and Solubility Advice: Batch Molecular Weight: 163.6 Some solutions can be difficult to obtain and can be encouraged Physical Appearance: White crystalline solid by rapid stirring, sonication or gentle warming (in a 45-60°C water bath).
    [Show full text]
  • Ion Channels
    UC Davis UC Davis Previously Published Works Title THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels. Permalink https://escholarship.org/uc/item/1442g5hg Journal British journal of pharmacology, 176 Suppl 1(S1) ISSN 0007-1188 Authors Alexander, Stephen PH Mathie, Alistair Peters, John A et al. Publication Date 2019-12-01 DOI 10.1111/bph.14749 License https://creativecommons.org/licenses/by/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: Ion channels. British Journal of Pharmacology (2019) 176, S142–S228 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels Stephen PH Alexander1 , Alistair Mathie2 ,JohnAPeters3 , Emma L Veale2 , Jörg Striessnig4 , Eamonn Kelly5, Jane F Armstrong6 , Elena Faccenda6 ,SimonDHarding6 ,AdamJPawson6 , Joanna L Sharman6 , Christopher Southan6 , Jamie A Davies6 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK 3Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 4Pharmacology and Toxicology, Institute of Pharmacy, University of Innsbruck, A-6020 Innsbruck, Austria 5School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 6Centre for Discovery Brain Science, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties.
    [Show full text]
  • Diamandis Thesis
    !"!#$ CHEMICAL GENETIC INTERROGATION OF NEURAL STEM CELLS: PHENOTYPE AND FUNCTION OF NEUROTRANSMITTER PATHWAYS IN NORMAL AND BRAIN TUMOUR INITIATING NEURAL PRECUSOR CELLS by Phedias Diamandis A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy. Department of Molecular Genetics University of Toronto © Copyright by Phedias Diamandis 2010 Phenotype and Function of Neurotransmitter Pathways in Normal and Brain Tumor Initiating Neural Precursor Cells Phedias Diamandis Doctor of Philosophy Department of Molecular Genetics University of Toronto 2010 &'(!)&*!% The identification of self-renewing and multipotent neural stem cells (NSCs) in the mammalian brain brings promise for the treatment of neurological diseases and has yielded new insight into brain cancer. The complete repertoire of signaling pathways that governs these cells however remains largely uncharacterized. This thesis describes how chemical genetic approaches can be used to probe and better define the operational circuitry of the NSC. I describe the development of a small molecule chemical genetic screen of NSCs that uncovered an unappreciated precursor role of a number of neurotransmitter pathways commonly thought to operate primarily in the mature central nervous system (CNS). Given the similarities between stem cells and cancer, I then translated this knowledge to demonstrate that these neurotransmitter regulatory effects are also conserved within cultures of cancer stem cells. I then provide experimental and epidemiologically support for this hypothesis and suggest that neurotransmitter signals may also regulate the expansion of precursor cells that drive tumor growth in the brain. Specifically, I first evaluate the effects of neurochemicals in mouse models of brain tumors. I then outline a retrospective meta-analysis of brain tumor incidence rates in psychiatric patients presumed to be chronically taking neuromodulators similar to those identified in the initial screen.
    [Show full text]
  • Transporters
    Alexander, S. P. H., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., Sharman, J. L., Southan, C., Davies, J. A., & CGTP Collaborators (2019). The Concise Guide to Pharmacology 2019/20: Transporters. British Journal of Pharmacology, 176(S1), S397-S493. https://doi.org/10.1111/bph.14753 Publisher's PDF, also known as Version of record License (if available): CC BY Link to published version (if available): 10.1111/bph.14753 Link to publication record in Explore Bristol Research PDF-document This is the final published version of the article (version of record). It first appeared online via Wiley at https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bph.14753. Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/ S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: Transporters. British Journal of Pharmacology (2019) 176, S397–S493 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Transporters Stephen PH Alexander1 , Eamonn Kelly2, Alistair Mathie3 ,JohnAPeters4 , Emma L Veale3 , Jane F Armstrong5 , Elena Faccenda5 ,SimonDHarding5 ,AdamJPawson5 , Joanna L Sharman5 , Christopher Southan5 , Jamie A Davies5 and CGTP Collaborators 1School of Life Sciences,
    [Show full text]
  • Guvacine Hydrochloride | Medchemexpress
    Inhibitors Product Data Sheet Guvacine hydrochloride • Agonists Cat. No.: HY-100809 CAS No.: 6027-91-4 Molecular Formula: C₆H₁₀ClNO₂ • Molecular Weight: 163.6 Screening Libraries Target: GABA Receptor Pathway: Membrane Transporter/Ion Channel; Neuronal Signaling Storage: Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month SOLVENT & SOLUBILITY In Vitro H2O : 41.67 mg/mL (254.71 mM; Need ultrasonic) DMSO : 1 mg/mL (6.11 mM; ultrasonic and warming and heat to 80°C) Mass Solvent 1 mg 5 mg 10 mg Concentration Preparing 1 mM 6.1125 mL 30.5623 mL 61.1247 mL Stock Solutions 5 mM 1.2225 mL 6.1125 mL 12.2249 mL 10 mM 0.6112 mL 3.0562 mL 6.1125 mL Please refer to the solubility information to select the appropriate solvent. BIOLOGICAL ACTIVITY Description Guvacine hydrochloride is an alkaloid from the nut of Areca catechu, acts as an inhibitor of GABA transporter, and dispalys modest selectivity for cloned GABA transporters with IC50s of 14 μM (human GAT-1), 39 μM (rat GAT-1), 58 μM (rat GAT-2), 119 μM (human GAT-3), 378 μM (rat GAT-3), and 1870 μM (human BGT-3). IC₅₀ & Target IC50: 14 μM (human GAT-1), 39 μM (rat GAT-1), 58 μM (rat GAT-2), 119 μM (human GAT-3), 378 μM (rat GAT-3), 1870 μM (human BGT-3)[1] In Vitro Guvacine hydrochloride is a potent inhibitor of GABA transporter, dispalys modest selectivity forcloned GABA transporters with IC50s of 14 μM (human GAT-1), 39 μM (rat GAT-1), 58 μM (rat GAT-2), 119 μM (human GAT-3), 378 μM (rat GAT-3), and [1] 1870 μM (human BGT-3).
    [Show full text]
  • Pharmacology of Basimglurant (RO4917523, RG7090), a Unique Mglu5 Negative Allosteric Modulator in Clinical Development for Depression
    JPET Fast Forward. Published on February 9, 2015 as DOI: 10.1124/jpet.114.222463 This article has not been copyedited and formatted. The final version may differ from this version. JPET #222463 Title page Pharmacology of basimglurant (RO4917523, RG7090), a unique mGlu5 negative allosteric modulator in clinical development for depression Lothar Lindemann*, Richard H. Porter, Sebastian H. Scharf, Basil Kuennecke, Andreas Bruns, Markus von Downloaded from Kienlin, Anthony C. Harrison, Axel Paehler, Christoph Funk, Andreas Gloge, Manfred Schneider, Neil J. Parrott, Liudmila Polonchuk, Urs Niederhauser, Stephen R. Morairty, Thomas S. Kilduff, Eric Vieira, Sabine jpet.aspetjournals.org Kolczewski, Juergen Wichmann, Thomas Hartung, Michael Honer, Edilio Borroni, Jean-Luc Moreau, Eric Prinssen, Will Spooren, Joseph G. Wettstein, Georg Jaeschke at ASPET Journals on September 27, 2021 Roche Pharmaceutical Research and Early Development, Discovery Neuroscience, Neuroscience, Ophthalmology, and Rare Diseases (NORD) (L.L., S.H.S., B.K., A.B., M.v.K., M.H., E.B., E.P., W.S., J.G.W.), Discovery Chemistry (E.V., S.K., J.W., G.J.), Operations for Neuroscience, Ophthalmology, and Rare Diseases (R.H.P., J.-L.M.), Pharmaceutical Sciences (A.H., A.P., C.F., A.G., M.S., N.P., L.P., U.N.), Small Molecules Process Research and Synthesis (T.H.), Roche Innovation Center Basel, Grenzacherstrasse 124, CH-4070 Basel, Switzerland Center for Neuroscience, Biosciences Division, SRI International, Menlo Park, California 94025, USA (S.R.M., T.S.K.) 1 JPET Fast Forward. Published on February 9, 2015 as DOI: 10.1124/jpet.114.222463 This article has not been copyedited and formatted.
    [Show full text]
  • GABA Receptor Gamma-Aminobutyric Acid Receptor; Γ-Aminobutyric Acid Receptor
    GABA Receptor Gamma-aminobutyric acid Receptor; γ-Aminobutyric acid Receptor GABA receptors are a class of receptors that respond to the neurotransmitter gamma-aminobutyric acid (GABA), the chief inhibitory neurotransmitter in the vertebrate central nervous system. There are two classes of GABA receptors: GABAA and GABAB. GABAA receptors are ligand-gated ion channels (also known as ionotropic receptors), whereas GABAB receptors are G protein-coupled receptors (also known asmetabotropic receptors). It has long been recognized that the fast response of neurons to GABA that is blocked by bicuculline and picrotoxin is due to direct activation of an anion channel. This channel was subsequently termed the GABAA receptor. Fast-responding GABA receptors are members of family of Cys-loop ligand-gated ion channels. A slow response to GABA is mediated by GABAB receptors, originally defined on the basis of pharmacological properties. www.MedChemExpress.com 1 GABA Receptor Agonists, Antagonists, Inhibitors, Activators & Modulators (+)-Bicuculline (+)-Kavain (d-Bicuculline) Cat. No.: HY-N0219 Cat. No.: HY-B1671 (+)-Bicuculline is a light-sensitive competitive (+)-Kavain, a main kavalactone extracted from Piper antagonist of GABA-A receptor. methysticum, has anticonvulsive properties, attenuating vascular smooth muscle contraction through interactions with voltage-dependent Na+ and Ca2+ channels. Purity: 99.97% Purity: 99.98% Clinical Data: No Development Reported Clinical Data: Launched Size: 10 mM × 1 mL, 50 mg, 100 mg Size: 10 mM × 1 mL, 5 mg, 10 mg (-)-Bicuculline methobromide (-)-Bicuculline methochloride (l-Bicuculline methobromide) Cat. No.: HY-100783 (l-Bicuculline methochloride) Cat. No.: HY-100783A (-)-Bicuculline methobromide (l-Bicuculline (-)-Bicuculline methochloride (l-Bicuculline methobromide) is a potent GABAA receptor methochloride) is a potent GABAA receptor antagonist.
    [Show full text]